Vascular biomarkers in the metabolic syndrome

Expert Review of Molecular Diagnostics

Volumn 9, Issue 3, 2009, Pages 209-215

  Thande, Njeri ^a   Rosenson, Robert S ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; N(G),N(G) DIMETHYLARGININE;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; STEM CELL;

ARGININE; BIOLOGICAL MARKERS; BLOOD VESSELS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 66749117769     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.2     Document Type: Editorial

References (85)

1. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28, 1769-1778 (2005).
2. Kahn R, Buse J, Ferrannini E et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289-2304 (2005).
3. Cornier M, Dabelea D, Hernandez TL et al. The metabolic syndrome. Endocr. Rev. 29, 777-822 (2008).
4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15, 539-553 (1988).
5. Grundy SM, Cleeman JI, Daniels SR et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752 (2005).
6. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 366, 1059-1062 (2005).
7. Einhorn D, Reaven GM, Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 288, 2709-2716 (2002).
8. Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Circulation 109, 433-438 (2004).
9. Hanley AJ, Karter AJ, Festa A et al. Factor analysis of metabolic syndromeusing directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes 51, 2642-2647 (2002).
10. Cheal KL, Abbasi F, Lamendola C et al. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53, 1195 -1200 (2004).
11. Petersen KF, Dufou r S, Savage DB et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA 104, I2587-2594 (2007).
12. Muniyappa R, Montagnani M, Koh KK et al. Cardiovascular actions of insulin. Endocr. Rev. 28, 463-491 (2007).
13. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr. Diab. Rep. 3, 279-288 (2003).
14. Potenza MA, Marasciulo FL, Chieppa DM et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am. J. Physiol. Heart Circ. Physiol. 289, H813-H822 (2005).
15. Montagnani M, Golovchenko K, Kim I et al. I nhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J. Biol. Chem. 277, 1794-1799 (2002).
16. Mukai Y, Wang CY, Rikitake Y et al. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 292, H1937-1942 (2007).
17. Kahn BB, Flier JS. Obesity and insulin resistance. J. Clin. Invest. 106, 473-481 (2000).
18. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin- resistant state. Diabetes Care 19, 390-393 (1996).
19. Boden G, Jadali F, White J et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J. Clin. Invest. 88, 960-966 (1991).
20. Santomauro AT, Boden G, Silva ME et al. Overnight lowering of free fatty acids with acipomox improves insulin resistance and glucose tolerance in obese diabetic and non-diabetic subjects. Diabetes 48, 1836-1841 (1999).
21. Lann D, LeRoith D. Insulin resistance as the underlying cause of the metabolic syndrome. Med. Clin. N. Am. 91, 1063 -1077 (2007).
22. Sutherland JP, Mckinley B, Eckel RH. The metabolic syndrome and inflammation. Metab. Syndr. Relat. Disord. 2, 82-104 (2004).
23. Alessi M, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb. Haemost. 99, 995-1000 (2008).
24. Hassinen M, Lakka TA, Komulainen P et al. C-reactive protein and metabolic syndrome in elderly women. Diabetes Care 29, 931-932 (2006).
25. Ridker PM, Buring JE, cook NR et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14, 719 initially healthy American women. Circulation 107, 391-397 (2003).
26. Deepa R, Velmuragan K, Arvind K et al. Serum levels of interleukin 6, C-reactive protein, vascular adhesion molecule 1 and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 55, 1232-1238.
27. Hung J, McQuillan BM, Chapman CM et al. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 25, 1268-1273 (2005).
28. Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J. Clin. Invest. 95, 2409-2415 (1995).
29. Mertens K, Verrijken A, Michiels JJ et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int. J. Obes. 30, 1308-1314 (2006).
30. Wannamethee SG, Lowe GD, Shaper AG et al. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 181(1), 101-108 (2005).
31. Folsom AR, Wu KK, Rosamond WD et al. Prospective study of hemostatic factors and incidence of coronary heart disease; the Atherosclerosis Risk in Communities (ARIC) study. Circulation 86, 1102-1108 (1997).
32. Smith FB, Lee AJ, Fowkes FG et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler. Thromb. Vasc. Biol. 17, 3321-3325 (1997).
33. Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98, 2241-2247 (1998).
34. Juhan-Vague I, Pyke SD, Allessi MC et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94, 2057-2063 (1996).
35. Duplain H, Bercelin R, Sartori C et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104, 342-345 (2001).
36. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 358, 2096-2097 (2001).
37. Shulze F, Weserman R, Schwedhelm E et al. Determination of ADMA using a novel ELISA assay. Clin. Chem. Lab. Med. 42, 1377-1383 (2004).
38. Valtonen P, Karppi J, Nyyssonen K et al. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 828, 97-102 (2005).
39. Boger RH, Bode-Boger SM, Thiele W et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95, 2068-2074 (1997).
40. Boger RH, Bode-Boger SM, Szuba A et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction; its role in hypercholesterolemia. Circulation 98, 1842-1847 (1998).
41. Surdacki A, Nowicki M, Sandmann J et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol. 33, 652-858 (1999).
42. Kielstein JT, Boger RH, Bode- Boger SM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 10, 594-600 (1999).
43. Stiihlinger MC, Abbasi F, Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287, 1420 -1426 (2002).
44. MacLaughlin T, Stuhlinger M, Lamendola C et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J. Clin. Endocrinol. Metab. 91, 1896-1900 (2006).
45. Kielstein JT, Bode-Boger SM, Klein G et al. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur. J. Clin. Invest. 33, 370-375 (2003).
46. Krempl TK, Maas R, Sydow K et al. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur. Heart J. 26, 1846-1851. (2005).
47. Zocali C, Benedetto FA, Maas R et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol. 13, 490 -496 (2002).
48. Nanayakkara PW, Teerlink T, Stehouwer CD et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascu lar cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int. 68, 2230-2236 (2005).
49. Iribarren C, Husson G, Sydow K et al. Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study. Eur. J. Cardiovasc. Prev. Rehabil. 14, 222-229 (2007).
50. Juonala M, Viikari J, Alfthan G et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 116, 1367-1373 (2007).
51. Garcia RG, Perez M, Maas R et al. Plasma concentrations of asymmetric dimethyl- arginine (ADMA) in metabolic syndrome. Int. J. Cardiol. 122, 176-178 (2007).
52. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 32, 126-136 (2006).
53. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 109: 1813-1818 (2004).
54. Leong T, Zylberstein D, Graham I et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women. Arteriosc. Thromb. Vasc. Biol. 28, 961-967 (2008).
55. Boger RH, Ron ES. L-arginine improves vascular function by overcoming the deletrious effects of ADMA, a novel cardiovascular risk factor. Altern. Med. Rev. 10, 14-23 (2005).
56. Cross JM, Donald AE, Kharbanda R et al. Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int. 60, 2318-2323 (2001).
57. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not -arginine, correct renal failure-associated endothelial dysfunction. Kidney Int. 53, 1068-1077 (1998).
58. 8 Wang T, Chen W, Cheng W et al. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am. J. Cardiol. 98, 1057-1062 (2006).
59. Asagami T, Abbassi F, Stuelinger M et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with Type 2 diabetes. Metabolism 51, 843-846 (2002).
60. Lu TM, Ding YA, Leu HB et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am. J. Cardiol. 94, 157-161 (2004).
61. Oguz A and Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with the metabolic syndrome. Int. Heart J. 49, 303-311 (2008).
62. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318, 1315-1321 (1988).
63. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 95, 233-238 (2004).
64. Yan SF, Ramasamy R, Naka Y et al. Glycation, inflammation and RAGE. A scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 93, 1159-1169 (2003).
65. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001).
66. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 21, 3-12 (2003).
67. Wautier MP, Chappey O, Corda S et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280, E685-E694 (2001).
68. Ramasamy R, Vannucci SJ, Yan SS et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15, 16R-28R (2005).
69. Ramasam R, Yan SS, Herold K et al. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfu nction and atherosclerosis. Ann. NY Acad. Sci. 1126, 7-13 (2008).
70. Brown LF, Fraser CG. Assay validation and biological variation of serum receptor for advanced glycation end-products. Ann. Clin. Biochem. 45, 518-519 (2008).
71. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348, 593-600 (2003).
72. Hofmann SM, Dong H, Zhu Li et al. Improved insulin sensitivity is associated with restricted intake of dietary glycooxidation products in db/db mouse. Diabetes 51, 2082-2089 (2002).
73. Sandu O, Song K, Cai W et al. Insulin resistance and Type 2 diabetes in high-fat fed mice are linked to high glycotoxin intake. Diabetes 54, 2314-2319 (2005).
74. Rashid G, Benchetrit S, Fishman E et al. Effect of advanced glycation end-products on gene expression and synthesis of TNF-a and endothelial nitric oxide synth ase by endothelial cells. Kidney Int. 66, 1099-1106 (2006).
75. Jia X, Olson DJ, Ross AR et al. Structural and functional changes in human insulin induced by methylglyoxal. FASEB J. 20, 1555-1557 (2006).
76. Miele C, Riboulet A, Maitan MA et al. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase Ca-mediated mechanism. J. Biol. Chem. 278, 47376- 47387 (2003).
77. Unoki H, Bujo H, Yamagishi S et al. Advanced gylcation end products attenuate cellular insulin sensitivity by increasing the generation on intracellular reactive oxygen species in adipocytes. Diabetes Res. Clin. Pract. 76, 236-244 (2007).
78. Gaens KH, van Der Kallen CJ, van Greevenbroek MM et al. Receptor for advanced glycation end product polymorphisms and Type 2 diabetes: the CODAM study. Ann. NY Acad. Sci. 1126, 162-165 (2008).
79. Sullivan CM, Futers TS, Barrett JH et al. RAGE polymorphisms and the heritability of insulin resistance: the LEEDS family study. Diabetes Vasc. Dis. Res. 2, 42-44 (2005).
80. Koyama H, Shoji T, Yokoyama H et al. Plasma levels of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 2587-2593 (2005).
81. Beisswenger PJ, Howell SK, Touchette AD et al. Metformin reduces systemic methylglyoxal levels in Type 2 diabetes. Diabetes 48, 198-202 (1999)
82. Miyata T, van Ypersele de Strihou C, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J. Am. Soc. Nephrol. 13, 2478-2487 (2002).
83. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007 (2005).
84. Dignat-George F, Sampol J. Circulating endothelial cells in vascular disorders; new insights into an old concept. Eur. J. Haematol. 65, 215-220 (2000).
85. Westerweel PE, Visseren FLJ, Hajer GR et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur. Heart J. 29(22), 2808-2817 (2008).